EUCTR2014-005263-33-DE
Active, not recruiting
Phase 1
Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum - EyNeP
Medizinische Fakultät der Universität Bonn0 sites15 target enrollmentFebruary 26, 2015
ConditionsChoroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticumMedDRA version: 20.0Level: PTClassification code 10037150Term: Pseudoxanthoma elasticumSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
DrugsEylea
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
- Sponsor
- Medizinische Fakultät der Universität Bonn
- Enrollment
- 15
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 8
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 7
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 3
To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment.ACTRN12613001020774Greenlane Clinical Centre Auckland District Health Board50
Completed
Not Applicable
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40
Completed
Phase 2
Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)Pseudoxanthoma ElasticumNCT02537054University Hospital, Bonn15
Completed
Not Applicable
Outcomes of intravitreal aflibercept (Eylea) treatment for treatment-naive contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed intravitreal ranibizumab in the first eyeeovascular age-related macular degenerationJPRN-UMIN000033786Seoul National University Hospital21
Active, not recruiting
Not Applicable
Treatment of a chorioretinal disease characterized by alterations in the elastic lamina of the Bruch's membrane, and which typically manifest themselves as streaks radial departure from the optic nerveEUCTR2014-000986-30-ITIRCCS Ospedale San Raffaele U.O. Oculistica